FY2025 · ended Dec 31, 2025 · Revenue $2.58B, +0.7% YoY · Filed Feb 13, 2026
Bio-Rad Laboratories, Inc. (BIO) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.6 billion and net income of $759.9 million. Free cash flow was $374.6 million. As of Sep 30, 2026 it held $7.9 billion in cash and investments and $1.4 billion in total debt.
Revenue (TTM)
$2.59B
+1.4% vs year-ago TTM
Net income (TTM)
$1.02B
+251.3% vs year-ago TTM
Operating cash flow (TTM)
$468.10M
-4.8% vs year-ago TTM
Free cash flow (TTM)
$329.10M
-2.3% vs year-ago TTM
EPS (TTM)
$37.96
+254.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
—
Net cash
$6.57B
as of Sep 30, 2026
Operating margin
-2.4%
FY 2026
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- BIO (NYSE), BIO-B (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hercules, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 12208
- Former names
- BIO RAD LABORATORIES INC (until Jun 18, 2018)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bruker Corp BRKR
- 10x Genomics, Inc. TXG
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.7B | $2.8B | $2.9B |
| Operating income | $47.2M | $269.0M | $337.8M | $482.6M | $500.3M |
| Net income | $759.9M | -$1.8B | -$637.3M | -$3.6B | $4.3B |
| Diluted EPS | $27.85 | — | -$21.82 | -$121.79 | $140.83 |
| Operating cash flow | $532.2M | $455.2M | $374.9M | $194.4M | $669.5M |
| Free cash flow | $374.6M | $289.6M | $218.2M | $81.6M | $535.7M |
| Total assets | $10.6B | $9.4B | $12.3B | $13.5B | $17.8B |
| Total liabilities | $3.1B | $2.8B | $3.6B | $3.9B | $4.1B |
| Stockholders' equity | $7.5B | $6.6B | $8.7B | $9.6B | $13.7B |
| Cash and investments | $7.6B | $6.5B | $9.3B | $10.6B | $15.3B |
| Total debt | $1.4B | $1.4B | $1.4B | $1.4B | $233.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Regulation FD disclosure
|
Aug 4, 2026 | Jul 31, 2026 |
| 10-Q | Quarterly report | Apr 30, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Apr 30, 2026 | Apr 30, 2026 |
All 1002 Bio-Rad Laboratories, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.